Population Pharmacokinetics and Exposure-Response Analyses of an MDM2 Inhibitor Milademetan

被引：0
|
作者：
Kang, Dongwoo [1 ]
Kumar, Prasanna [1 ]
Zernovak, Oleg [1 ]
Song, Saeheum [1 ]
Xiong, Yuan [2 ]
Bergsma, Tim [2 ]
Lovern, Mark [2 ]
Yin, Ophelia [1 ]
机构：
[1] Daiichi Sankyo Inc, Basking Ridge, NJ USA
[2] Certara, Princeton, NJ USA
来源：
JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS | 2018年 / 45卷
关键词：
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
M-045
引用
下载
收藏
页码：S24 / S24
页数：1
相关论文
共 50 条
  • [41] Population pharmacokinetics and exposure-response analyses of polatuzumab vedotin in patients with previously untreated DLBCL from the POLARIX study
    Deng, Rong
    Gibiansky, Leonid
    Lu, Tong
    Flowers, Christopher R.
    Sehn, Laurie H.
    Liu, Qi
    Agarwal, Priya
    Liao, Michael Z.
    Dere, Randall
    Lee, Calvin
    Man, Gabriel
    Hirata, Jamie
    Li, Chunze
    Miles, Dale
    CPT-PHARMACOMETRICS & SYSTEMS PHARMACOLOGY, 2024, 13 (06): : 1055 - 1066
  • [42] Upadacitinib Population Pharmacokinetics and Exposure-Response Relationships in Ulcerative Colitis Patients
    Ponce-Bobadilla, Ana Victoria
    Stodtmann, Sven
    Eckert, Doerthe
    Zhou, Wen
    Liu, Wei
    Mohamed, Mohamed-Eslam F.
    CLINICAL PHARMACOKINETICS, 2023, 62 (01) : 101 - 112
  • [43] POPULATION PHARMACOKINETICS (PK) OF LEBRIKIZUMAB AND EXPOSURE-RESPONSE (ER) ANALYSES OF PHASE III STUDIES IN SEVERE ASTHMA PATIENTS
    Zhu, R.
    Dirks, N. L.
    Vadhavkar, S.
    Jin, J. Y.
    Holweg, C.
    Olsson, J.
    Matthews, J.
    Putnam, W.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2017, 101 (S1) : S95 - S95
  • [44] POPULATION PHARMACOKINETICS AND EXPOSURE-RESPONSE ANALYSIS OF AMG 333, A TRPM8 INHIBITOR FOR MIGRAINE PROPHYLAXIS.
    Yuraszeck, T.
    Davis, C.
    Gabriel, K.
    Kasichayanula, S.
    Palaparthy, R.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2016, 99 : S72 - S72
  • [45] Population Pharmacokinetics and Exposure-Response (Efficacy and Safety/Tolerability) of Empagliflozin in Patients with Type 2 Diabetes
    Baron, Kyle T.
    Macha, Sreeraj
    Broedl, Uli C.
    Nock, Valerie
    Retlich, Silke
    Riggs, Matthew
    DIABETES THERAPY, 2016, 7 (03) : 455 - 471
  • [46] DNA damage response to the Mdm2 inhibitor Nutlin-3
    Verma, Rajeev
    Rigatti, Marc J.
    Belinsky, Glenn S.
    Godman, Cassandra A.
    Giardina, Charles
    BIOCHEMICAL PHARMACOLOGY, 2010, 79 (04) : 565 - 574
  • [47] Population Pharmacokinetics and Exposure-Response Modeling Analyses of Golimumab in Children and Young Adults With Recently Diagnosed Type 1 Diabetes
    Lee, Jong Bong
    Zhou, Wangda
    Xu, Zhenhua
    Hedrick, Joseph A.
    Leu, Jocelyn H.
    JOURNAL OF CLINICAL PHARMACOLOGY, 2023, 63 (06): : 721 - 731
  • [48] A First-in-Human Phase I Study of Milademetan, an MDM2 Inhibitor, in Patients With Advanced Liposarcoma, Solid Tumors, or Lymphomas
    Gounder, Mrinal M.
    Bauer, Todd M.
    Schwartz, Gary K.
    Weise, Amy M.
    LoRusso, Patricia
    Kumar, Prasanna
    Tao, Ben
    Hong, Ying
    Patel, Parul
    Lu, Yasong
    Lesegretain, Arnaud
    Tirunagaru, Vijaya G.
    Xu, Feng
    Doebele, Robert C.
    Hong, David S.
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (09) : 1714 - +
  • [49] ABATACEPT POPULATION PHARMACOKINETICS AND EXPOSURE-RESPONSE ANALYSES FOR DOSE RECOMMENDATION OF SC AND IV ABATACEPT IN PATIENTS WITH PSORIATIC ARTHRITIS.
    Li, X.
    Passarell, J. A.
    Morris, D.
    Murthy, B.
    Girgis, I. G.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2018, 103 : S77 - S77
  • [50] Population Pharmacokinetics of Oral Azacitidine, and Exposure-Response Analysis in Acute Myeloid Leukemia
    Gaudy, Allison
    Laille, Eric
    Bailey, Rochelle
    Zhou, Simon
    Skikne, Barry
    Beach, C. L.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2023, 114 (04) : 845 - 852
12345